KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Finished Goods: 2013-2024

Historic Finished Goods for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Dec 2024 value amounting to $16.4 million.

  • Supernus Pharmaceuticals' Finished Goods fell 31.28% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year decrease of 31.28%. This contributed to the annual value of $16.4 million for FY2024, which is 45.05% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Finished Goods of $16.4 million as of FY2024, which was down 45.05% from $29.9 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Finished Goods registered a high of $35.0 million during FY2022, and its lowest value of $16.4 million during FY2024.
  • Its 3-year average for Finished Goods is $27.1 million, with a median of $29.9 million in 2023.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Finished Goods skyrocketed by 92.17% in 2021, and later plummeted by 45.05% in 2024.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Finished Goods stood at $17.1 million in 2020, then soared by 92.17% to $32.9 million in 2021, then grew by 6.34% to $35.0 million in 2022, then dropped by 14.54% to $29.9 million in 2023, then crashed by 45.05% to $16.4 million in 2024.